Exact Sciences

1D
1W
1M
3M
YTD
1Y
5Y
ALL

Why Robinhood?

You can watch Exact Sciences and buy or sell other stocks, ETFs, and their options commission-free!

About EXAS

EXACT Sciences Corp. is a cancer screening and diagnostics company. The firm focuses on the early detection and prevention of some forms of cancer. 

CEO
Kevin T. Conroy
CEOKevin T. Conroy
Employees
7,200
Employees7,200
Headquarters
Madison, Wisconsin
HeadquartersMadison, Wisconsin
Founded
1995
Founded1995
Employees
7,200
Employees7,200

EXAS Key Statistics

Market cap
20.02B
Market cap20.02B
Price-Earnings ratio
-94.98
Price-Earnings ratio-94.98
Dividend yield
Dividend yield
Average volume
2.35M
Average volume2.35M
High today
High today
Low today
Low today
Open price
Open price
Volume
0.00
Volume0.00
52 Week high
$104.98
52 Week high$104.98
52 Week low
$38.81
52 Week low$38.81

Stock Snapshot

With a market cap of 20.02B, Exact Sciences(EXAS) trades at $104.91. The stock has a price-to-earnings ratio of -94.98.

On 2026-04-15, Exact Sciences(EXAS) shares started trading at —, with intraday highs of — and lows of —.

Trading volume for Exact Sciences(EXAS) stock has reached 0, versus its average volume of 2.35M.

The stock's 52-week range extends from a low of $38.81 to a high of $104.98.

The stock's 52-week range extends from a low of $38.81 to a high of $104.98.

People also own

Based on the portfolios of people who own EXAS. This list is generated using Robinhood data, and it’s not a recommendation.

Similar Marketcap

This list is generated by looking at the six larger and six smaller companies by market cap in relation to this company.

Popular Stocks

This list is generated by looking at the top 100 stocks and ETFs most commonly held by Robinhood customers and showing a random subset

Newly Listed

This list is generated by showing companies that recently went public.

All investments involve risks, including the loss of principal. Securities trading offered through Robinhood Financial LLC, Member SIPC and a registered broker-dealer. Options are risky and aren’t suitable for all investors. To learn more about risks, read the Options Disclosure Document.